<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Orthovita Incorporated</title>
	<atom:link href="http://www.stockbloghub.com/tag/orthovita-incorporated/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(KNSY) Kensey Beats Consensus Estimate</title>
		<link>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227</link>
		<comments>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227#comments</comments>
		<pubDate>Mon, 24 Aug 2009 20:39:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Medical Instruments & Supplies]]></category>
		<category><![CDATA[Kensey Nash Corporation]]></category>
		<category><![CDATA[KNSY]]></category>
		<category><![CDATA[Orthovita Incorporated]]></category>
		<category><![CDATA[Spectranetics Corporation]]></category>
		<category><![CDATA[SPNC]]></category>
		<category><![CDATA[St. Jude Medical Inc]]></category>
		<category><![CDATA[STJ]]></category>
		<category><![CDATA[VITA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13227</guid>
		<description><![CDATA[Kensey Nash Corp. (KNSY) recently reported strong results for the fourth quarter and full year 2009. Quarterly profit came in at 41 cents per share, compared to the Zacks Consensus Estimate of 38 cents and the year-ago loss of 9 cents per share. Quarterly Results Sales Net sales in the quarter were $20.5 million, down about 7% year over year. In terms of business segments, sales of Biomaterials products fell 8% year over year to $12.3 million. Within this segment, Orthopaedic revenue declined 16% year over year to $7 million on lower sales of sports medicines due to the ongoing economic turbulence. This was partly offset by higher sales of the Vitoss Bioactive Foam products to its customer Orthovita Inc. (VITA). Cardiovascular sales rose 8% year over year to $4.5 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/24/knsy-kensey-beats-consensus-estimate/13227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

